GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XSpray Pharma AB (OSTO:XSPRAY) » Definitions » EV-to-EBITDA

XSpray Pharma AB (OSTO:XSPRAY) EV-to-EBITDA : -12.40 (As of Jun. 23, 2024)


View and export this data going back to 2017. Start your Free Trial

What is XSpray Pharma AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, XSpray Pharma AB's enterprise value is kr2,537.69 Mil. XSpray Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was kr-204.58 Mil. Therefore, XSpray Pharma AB's EV-to-EBITDA for today is -12.40.

The historical rank and industry rank for XSpray Pharma AB's EV-to-EBITDA or its related term are showing as below:

OSTO:XSPRAY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -217.44   Med: -32.64   Max: 301.29
Current: -12.4

During the past 9 years, the highest EV-to-EBITDA of XSpray Pharma AB was 301.29. The lowest was -217.44. And the median was -32.64.

OSTO:XSPRAY's EV-to-EBITDA is ranked worse than
100% of 462 companies
in the Biotechnology industry
Industry Median: 8.545 vs OSTO:XSPRAY: -12.40

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-23), XSpray Pharma AB's stock price is kr77.20. XSpray Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was kr-7.680. Therefore, XSpray Pharma AB's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


XSpray Pharma AB EV-to-EBITDA Historical Data

The historical data trend for XSpray Pharma AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XSpray Pharma AB EV-to-EBITDA Chart

XSpray Pharma AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only -29.08 -74.79 -12.04 -9.62 -6.60

XSpray Pharma AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.72 -5.43 -5.89 -6.60 -6.10

Competitive Comparison of XSpray Pharma AB's EV-to-EBITDA

For the Biotechnology subindustry, XSpray Pharma AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XSpray Pharma AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XSpray Pharma AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where XSpray Pharma AB's EV-to-EBITDA falls into.



XSpray Pharma AB EV-to-EBITDA Calculation

XSpray Pharma AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=2537.694/-204.583
=-12.40

XSpray Pharma AB's current Enterprise Value is kr2,537.69 Mil.
XSpray Pharma AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-204.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


XSpray Pharma AB  (OSTO:XSPRAY) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

XSpray Pharma AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=77.20/-7.680
=At Loss

XSpray Pharma AB's share price for today is kr77.20.
XSpray Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-7.680.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


XSpray Pharma AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of XSpray Pharma AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


XSpray Pharma AB (OSTO:XSPRAY) Business Description

Traded in Other Exchanges
Address
Rasundavagen 12, Solna, SWE, 169 67
XSpray Pharma AB is a product development company with several product candidates in clinical development. It develops, sells and licenses generic versions of marketed cancer drugs, protein kinase inhibitors. The company primarily develops protein kinase inhibitors (PKI) are the largest segment within cancer drugs targeted for cancer treatment.

XSpray Pharma AB (OSTO:XSPRAY) Headlines

No Headlines